Physician profile
John Gregory Citti
NPI 1184630824
$17,628.10
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,894 · 2020: $4,987 · 2021: $3,947 · 2022: $3,368 · 2023: $2,413 · 2024: $17.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,763.49 | 2019-2021 | |
| Amgen INC. | $2,805.69 | 2019-2023 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,211.60 | 2019-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $1,116.53 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $960.98 | 2019-2023 | |
| Abbvie INC. | $715.93 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $579.99 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $541.97 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $499.87 | 2019-2021 | |
| Daiichi Sankyo INC. | $474.16 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $456.90 | 2020-2023 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $447.43 | 2019-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.56 | 2019-2023 | Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $307.36 | 2022 | |
| Astellas Pharma US INC | $303.16 | 2020-2023 | Myrbetriq, Veozah |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Citti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.